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Abstract: Acute myeloid leukemia (AML) is a heterogeneous disease, and communication between
leukemic cells and their neighboring leukemia-supporting normal cells is involved in leukemogenesis.
The bone marrow cytokine network is therefore important, and the mediator release profile seems
more important than single mediators. It is not known whether the characterization of primary AML
cell proteomes reflects the heterogeneity of the broad and dynamic constitutive mediator release
profile by these cells. To address this, we compared the intracellular levels of 41 proteins in 19 AML
patients with the constitutive extracellular release during in vitro culture, including chemokines,
growth factors, proteases, and protease regulators. The constitutive release of most mediators
showed a wide variation (up to 2000-fold differences) between patients. Detectable intracellular
levels were seen for 10 of 41 mediators, but for most of these 10 mediators we could not detect
significant correlations between the constitutive release during in vitro culture and their intracellular
levels. Intracellular protein levels in primary human AML cells do not reflect the dynamics, capacity,
and variation between patients in constitutive mediator release profiles. Measurements of these
profiles thus add complementary information to proteomic detection/quantification regarding the
heterogeneity of the AML cell contributions to the bone marrow cytokine network.
Keywords: acute myeloid leukemia; cytokine; protease; constitutive secretion; proteomics
1. Introduction
Acute myeloid leukemia (AML) is an aggressive malignancy characterized by the infiltration of
immature leukemia blasts in the bone marrow [1]. Several nonleukemic bone marrow cells support
the development of the disease, including the various cells of the stem cell niches that support the
maintenance of the most immature leukemic stem cells [2,3]. The bidirectional crosstalk between
leukemic and non-leukemic cells is mediated both by direct cell–cell contact and through the release of
soluble mediators into their common bone marrow microenvironment [4–6]. The constitutive release
(here defined as mediators secreted without specific stimuli) of a wide range of soluble mediators by
the primary human AML cells is thought to be an important part of this crosstalk. This release is also
important for autocrine loops and, thereby, the spontaneous proliferation of AML cells, and the ability
of autocrine proliferation is also associated with the prognosis [7].
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AML is a very heterogeneous disease [1], and proteomic investigations can be used to further
characterize this heterogeneity [8–11]. A wide variation in the constitutive release of several soluble
mediators is a part of this patient heterogeneity [12,13]. Previous studies of this release have been
based on the detection of extracellular mediator levels after in vitro culture of enriched AML cells
under highly standardized conditions, i.e., evaluation of mediator release in a dynamic model, and
the differences between patients in this assay are even associated with prognosis. However, this
possible prognostic impact needs to be further investigated, but biological characteristics detected
during in vitro culture are not suitable for implementation in clinical studies or routine clinical practice.
For these reasons, we have investigated whether an analysis of intracellular mediator levels, i.e., the
snapshot of intracellular proteins at the time of sample collection, reflects the dynamic process of
constitutive mediator release from these cells. We then compared the proteomic quantitation of cellular
soluble mediators in enriched primary AML cells with the constitutive extracellular mediator release
during standardized in vitro culture of the leukemic cells.
2. Materials and Methods
2.1. Collection and Preparation of Primary AML Patient Cells
The study was approved by the local Ethics Committee (Regional Ethics Committee III, University
of Bergen; REK 2013/634), and samples were collected after written informed consent. AML blasts were
derived from 19 unselected patients admitted to our hospital for treatment of acute myeloid leukemia
(7 females and 12 males; median age 52 years with range 18–68 years). The present study included
all patients from a defined geographical area and during a defined time period who were below
70 years of age, had circulating AML blasts in the peripheral blood, and were regarded to be fit for
intensive (i.e., potentially curative) antileukemic treatment. The patient characteristics are summarized
in Table 1. A major part of the patients had de novo AML with normal karyotype. Primary AML
cells were isolated from peripheral blood by density gradient separation (Lymphoprep; Axis-Shield,
Oslo, Norway; specific density 1.077 g/mL). All patients showed high levels (>20 × 109/L) and/or
percentage (>80%) of circulating AML blasts, and a highly enriched blast population could thereby
be prepared by density gradient separation alone [14–16]. The prepared leukemic cell populations
contained at least 90% blasts and the cells were stored in liquid nitrogen until used.
Table 1. Biological and clinical characteristics of the 19 AML patients included in the study.
Patient Characteristics Cell Morphology Cell Genetics
Age FAB classification Cytogenetics
Median (years) 52 M0 1 Favorable 3
Range (years) 18–68 M1 5 Intermediate 1
M2 3 Normal 13
Gender M4 4 Adverse 2
Females 7 M5 6
Males 12 Flt3 mutations
ITD 9 1
Disease CD34 receptor Wild-type 10
De novo AML 14 Negative (≤20%) 13





1 One of these patients has an additional point mutation at D835.
2.2. Protein Analyses and In Vitro Culture
Primary AML cells from all 19 patients were thawed and immediately processed for proteomic
analysis/quantification according to the sample preparation protocol previously described in
detail [8,11]. Briefly, the cells were lysed in 4% SDS/0.1M Tris-HCl pH 7.6, and 20 µg protein samples
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were prepared according to the filter-aided sample preparation protocol [17]. For proteomic analysis,
approximately 1 µg per sample, dissolved in 2% acetonitrile (ACN) and 1% formic acid (FA), was injected
into an Ultimate 3000 Rapid Separation LC system (Thermo Scientific, Sunnyvale, California, CA, USA)
coupled to a QExactive HF mass spectrometer (MS) (Thermo Scientific, Bremen, Germany) equipped
with an EASY-spray ion source (Thermo Scientific). The peptides were pre-concentrated on a precolumn
(Acclaim PepMap100, 2 cm × 75 µm I.D. nanoViper column, packed with 3 µm C18 beads with pore size
100Å), and separated on a 50 cm-long analytical column (Acclaim PepMap RSLC, 50 cm × 75 µm I.D.
EASY-spray column, packed with 2 µm C18 beads with pore size 100Å) at a flow rate of 200 nL/min. The
peptides were eluted by a binary gradient of solvent A (0.1% FA) and solvent B (0.1% FA/ACN) with the
following 195 min gradient composition: 5% B during trapping from 0 to 5 min followed by increase to
8% B from 5 to 5.5 min, then to 24% B from 5.5 to 115 min, to 35% B from 115 to 140 min, and to 90% B
from 140 to 155 min. Hold at 90% B for 15 min and ramped to 5% B from 170 to 195 min.
The QExactive HF was operated in data-dependent acquisition (DDA) mode, thus switching
between survey full scan MS and MS/MS acquisition. The full scans (from m/z 375–1500) were acquired
in profile mode with a resolution of R = 120,000 at 200 m/z, an automatic gain control (AGC) target
value of 3 × 106 and maximum injection time (IT) of 100 ms. The top 12 precursors (above the intensity
threshold of 5 × 104 counts) were sequentially isolated for MS/MS. The scans were acquired in centroid
mode with a resolution of R = 30,000, an AGC target value of 1 × 105 and a maximum IT of 110 ms.
Normalized collision energy was set to 28%, the isolation window was 1.6 m/z (offset 0.3 m/z) and
the dynamic exclusion lasted for 25 s. Furthermore, for spray and ion-source parameters, the ion spray
voltage was at 1800 V, no sheath and auxiliary gas flow, and the capillary temperature was at 260 ◦C.
The raw MS files were searched in MaxQuant (v.1.5.6.0) [18] using default parameters, with the
following exceptions: Gln conversion to pyro-Glu was included as a variable modification, trypsin was
used for proteolytic digestion, peptide length was set to 6 amino acids, the match-between-runs option
was enabled, and the minimum ratio count was set to 1 for label-free quantitation (LFQ) (i.e., the same
peptide needs to be present in at least two samples for quantification). The cellular protein levels were
relatively quantified using the MaxLFQ algorithm [19], and these intracellular levels are presented as
the relative LFQ intensity defined as the normalized relative protein abundance compared across the
MS runs.
Our in vitro model for investigation of constitutive mediator release has been previously described
in detail [12,13,20]. Briefly, supernatants were collected from all patients’ AML cells after being cultured
alone for 48 h in Stem Span SFEMTM medium (Stem Cell Technologies; Vancouver, BC, Canada) in
24-well culture plates (1 × 106 cells per mL; Nunclon, Roskilde, Denmark). The levels of 41 mediators
were analyzed either by Luminex assays or ELISA analyses, as described previously [12,13,21].
The raw data of constitutive mediator release for the 19 patients of interest were extracted from
our previous studies comprising 79 patients, in which 7 of the 19 patients were identified with low, 4
with intermediate, and 8 with high mediator release profiles [13].
Spearman’s test was used to assess the correlation between the intracellular and extracellular
levels of the mediators (GraphPad Prism version 7.00, California, CA, USA).
3. Results and Discussion
AML is a bone marrow disease, and the constitutive release of soluble mediators by leukemic cells
is important for the communication between these cells and their neighboring AML-supporting cells
in the common bone marrow microenvironment [4,5,22–24]. The constitutive release may even have a
prognostic impact [13], and one can therefore argue that this parameter should be further evaluated
in future clinical studies as a possible prognostic factor. However, in vitro culture is not suitable as
a biomarker in clinical studies or routine clinical practice, and an important question is therefore
whether a snapshot examination of intracellular mediator levels reflects and can replace the more
complex analysis of the dynamic constitutive release, the patient heterogeneity, and the complexity
of the release profile. We investigated the release of a wide range of mediators in our previously
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established and standardized in vitro culture model, where the prognostic impact was observed, and
we compared the results from this model with the analyses of intracellular mediator levels. Thus,
our main intention in the present study was to investigate whether snapshot analysis of intracellular
mediator levels reflects the dynamic process of extracellular release. A proteomic approach offers the
possibility to analyze a large number of cellular proteins to analyze the intracellular mediator profile
by itself and as an interacting part of a complex biological context. We therefore explored whether
such an intracellular snapshot reflects the dynamics (i.e., variation between patients, complexity of the
release profile) of the constitutive release that is seen in the in vitro culture model.
We investigated the constitutive release of 41 soluble mediators by in vitro cultured primary
human AML cells derived from 19 patients; for 38 of them, detectable release was seen for a majority
of patients, while ADAM12 had undetectable levels in all patients. The overall results are summarized
in Table 1. It can be seen that the large majority of mediators showed a wide variation among
patients, and the fold variation between patients with detectable release was more than 2000-fold
for several mediators. Investigation of the technical variation (data not shown) between duplicate
determinations showed <10% and usually <5% variation, and can thus not explain the large variation
between the patients. Furthermore, all samples were investigated in the same ELISA or Luminex
assay to avoid inter-assay variations. Lastly, the reproducibility of measurements of 19 mediators in
independent experiments (i.e., thawing of a second ampulla, separate cell culture preparations, and
separate mediator analyses) was assessed for 13 random patients from the biobank. We observed
strong correlations between mediator levels detected in our present article, and levels detected in
these completely independent experiments for 17 of the 19 tested mediators (r-values >0.49 and
p-values < 0.04). For 13 of these 19 mediators the r-values were >0.60.
We identified 5790 protein groups in our proteomic data after removing reverse hits and proteins
only identified by site. The number of quantified proteins per patient varied from 3823 to 5102.
Of these, 5777 proteins had a quantitative value, and only 10 of the 41 mediators of interest were
identified/quantified (Table 2), indicating low intracellular concentration for the majority of the
41 mediators compared to many other cellular proteins. The number of peptides quantified per protein
varied among the patient samples: BSG, CASP1, ELANE were quantified with two or more peptides in
every patient sample, while CCL5 was quantified with one or two peptides in the seven patient samples
with measurable abundance (Supplemental Table S2). The peptides quantified for MMP-2 were also
present in the sequence of MMP-7, hence, MMP-2 was not considered as quantified. The ten mediators
that could be quantified included nine proteases/protease regulators and only one chemokine (CCL5).
Thus, of 41 the selected mediators in Supplemental Table S1, only one of eleven chemokines was
quantified, while none of the six interleukins or the eight growth factors was quantified among the
many thousands of proteins from the proteomics approach. Constitutive CCL5 release by the in vitro
cultured AML cells was detected for all 19 patients in the Luminex assay, whereas it was only detected
for 7 patients with the proteomic approach. BSG was the only protein detected in all 19 patients
with both approaches. The fact that only one chemokine and nine proteases/protease regulators
were found intracellularly (using proteomic quantification), while 38 of our selected mediators were
detected extracellularly (in the supernatants after 48 h in vitro cell culturing), may suggest that many
chemokines, growth factors, and interleukins are of low abundance intracellularly, and thus challenges
protein detection with our proteomic procedure.
Proteomic analysis of the AML cells allows identification and quantification of the proteins
and their relative abundance in a particular compartment at a specific time. This analysis therefore
represents a static snapshot of ongoing biological processes. By exploring the correlation of intracellular
protein abundances with the concentration released into the media after 48 h in vitro culturing, we
intended to investigate the dynamics of mediator release in the 19 AML patients (Figure 1).
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Table 2. Soluble mediator levels detected during constitutive in vitro culture and by the proteomic analysis. The table shows a comparison for the 10 soluble mediators
that showed quantifiable levels in the proteomic analysis. For the constitutive mediator release during in vitro culture studies, we present the number of patients with
detectable levels, median level (pg/mL), variation range, and fold variation (i.e., the fold change between the highest and lowest quantitative value in each assay) for
each of the mediators, measured with Luminex/ELISA. The proteomic results are presented as the number of patients with quantified levels and the variation among
these patients. The results from the statistical analyses (Spearman’s test, ns means not statistically significant) are presented in the right column.
Mediator
Detectable Constitutive Release During in Vitro Culture Quantifiable Levels in Proteomic Analysis Correlation
(p-Value)Number Median Range Fold Variation Number Fold Variation
CCL5 19 56.3 17.4–2481 143 7 27 0.0480
MMP9 12 23,957 1123–261,935 233 13 2361 ns
TIMP1 (tissue inhibitor of MMPs) 19 2298 580–34,789 60 17 95 ns
Caspase 1/CASP1 9 8.1 1.0–28.0 28 19 163 ns
BSG (basigin) 19 401 61.2–1876 31 19 4.5 ns
CFD (complement factor D) 13 4106 123–18,426 150 18 139 0.0553
Cystatin B/CSTB 18 2846 165–17,949 109 18 121 ns
Cystatin C/CST3 19 3075 233–52,208 224 16 19 0.0078
Neutrophil elastase/ELANE 13 11,224 1072–203,665 190 19 835 ns
Serpin E1 19 1131 36.2–23,925 661 14 412 ns
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Figure 1. Comparison of constitutive mediator release during in vitro culture and the corresponding
proteomic abundance of cellular protein levels (relative intensity). Cellular levels in the proteomic
analysis were quantified for 10 of the 41 mediators; this included the chemokine CCL5 (quantified
intracellular levels for 7 patients/detectable extracellular release during culture for 19 patients) together
with the proteases or protease regulators CFD (18/13 patients), TIMP1 (17/19 patients), MMP9 (13/12
patients), serpin E1 (14/19 patients), BSG (19/19 patients), cystatin B (18/18 patients), cystatin C (16/19
patients), neutrophil elastase /ELANE (19/13 patients), and caspase 1 (19/9 patients). The figure
presents the results for all mediators showing quantifiable levels in the proteomic analysis, and the
results are presented as the intracellular protein level (relative label-free quantitation (LFQ) intensity,
x-axis) versus the corresponding supernatant concentrations (i.e., released soluble protein, pg/mL,
y-axis). The corresponding Spearman r- and p-values are indicated in the figure for each of the
10 mediators.
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The question of interest is what the different correlation analyses of these soluble mediators reflect.
There are three expected outcomes of the analyses: (1) correlation of intracellular and extracellular
levels, indicating a steady relationship between protein synthesis and mediator release; (2) high
intracellular levels and low constitutive release of soluble mediators, indicating mainly intracellular
protein functions; or (3) low intracellular levels and high constitutive release of soluble mediators,
indicating rapid mediator release for extracellular functions. A correlation between the in vitro culture
and ex vivo proteomic levels was only seen for CCL5, CFD, and cystatin C/CST3; a highly significant
correlation was seen for cystatin C/CST3 (p = 0.0078, r = 0.65) whereas only borderline significance
was reached for CCL5 (p = 0.048, r = 0.79) and CFD (p = 0.055, r = 0.55). For the seven other mediators,
the p-values did not obtain statistical significance, and r-values were generally <0.25 (Figure 1).
Interestingly, for several of these mediators (e.g., TIMP1 and cystatin B), we observed correlation plots
with a combination of the expected outcomes, potentially reflecting the large heterogeneity among
the patients. For example, the intracellular and released levels of TIMP1 seem to correlate for some
patients, however, while it was not quantified intracellularly for one patient with high released levels, it
had the highest intracellular levels in another patient of which the released level was below the median
(Supplemental Table S1). By contrast, cystatin B seems to be more heterogeneous at the intracellular
level compared to the released level, although the fold variation (i.e., between the highest and lowest
level) is relatively similar for both assays. A subset of the patients demonstrated large variations in
their constitutive release of serpin E1, while the intracellular levels in these particular patients were
relatively similar.
We hypothesize that the lack of correlation between intracellular and released extracellular levels
for most mediators indicates that the intracellular levels, at least for certain mediators, reflect additional
intracellular functions rather than the capacity of extracellular release. This may also be the explanation
for the similar lack of correlation between intracellular and extracellular levels of osteopontin [25].
At the same time, higher extracellular release may represent a different phenotype with a more
pronounced cell–cell communication. With exception of CCL5, the detected mediators are all proteases
and protease regulators. VEGF shows both intra- and extracellular autocrine signaling [26], and the
same may also be true for other soluble mediators. Several matrix metalloproteases, various TIMPs,
CFD, and cystatins, seem to be important for intracellular functions with regard to signaling, regulation
of apoptosis, and regulation of mitochondrial or nuclear functions [27–36].
To decrease the risk of inducing biological alterations in the leukemic cells by more extensive
cell separation procedures [15,16], we only investigated patients with a high peripheral blood blast
count/percentage. We therefore emphasize that our present observations may be representative only
for this particular patient subset with relatively high peripheral blood blast counts.
It has been suggested by others that cryopreserved AML cells should be cultured in vitro for a
short period before proteomic analysis to reduce the effects of the cryopreservation-induced stress on
the leukemic cells [37]. However, additional in vitro culture will induce the process of spontaneous or
in vitro induced apoptosis in primary AML cells [38], and this ongoing biological process may affect
the proteome. To avoid the influence of this additional factor and to analyze a sample condition more
likely to be used in clinical practice, we investigated the leukemic cells immediately after thawing in
our proteomic studies, but it should be noted that the in vitro cultured cells may differ from these cells.
We have previously shown that cryopreservation and thawing of primary human AML cells
will alter the proteome and phosphoproteome [8,39], including proteins involved in the mitotic
processes and signaling downstream to lectin receptors and CLEC7A signaling, that was reduced
in cryopreserved cells [8]. However, although other patient samples were used in our previous
studies, none of the proteins explored here (and quantified in our previous proteomic studies)
were significantly altered according to the applied statistics [8]. Thus, in our opinion, it is less
likely that the lack of correlation between proteomic and in vitro culture levels are caused by
cryopreservation-induced alterations.
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Our previous studies suggest that the capacity of constitutive mediator release is associated with a
favorable prognosis [13], and it may therefore be of interest to evaluate the constitutive release in future
clinical studies to clarify whether it is an independent prognostic parameter or only a part of a more
complex phenotype that is associated with already identified independent prognostic markers. In vitro
culturing is not suitable for routine clinical practice, and analysis of mediator expression at the mRNA
level is possibly not reliable because there is not always a correlation between mRNA expression and
protein level/secretion [12,13]. Our preliminary results suggest that mRNA and protein expression of
genes that are important for transcriptional regulation and intracellular organellar functions/trafficking
(especially the V-ATPase complex) may reflect constitutive cytokine release, and may thereby be used
as a biomarker for this functional characteristic [13].
4. Conclusions
Communication between malignant and nonmalignant neighboring cells through the cytokine
network is important in AML. AML cells show constitutive release of a wide range of soluble
mediators, and the overall release profile or combined effects of several mediators may then be
more important than the effects of single mediators. Our study shows that for most mediators, the
ability of constitutive extracellular release by primary human AML is best evaluated by in vitro
culture, and not by analyzing intracellular levels as a static representation of the potential secretome.
However, several soluble mediators demonstrate a wide variation between patients both intracellularly
and when constitutively released, thus reflecting the large heterogeneity in AML. A combination of
different methodological strategies may be essential to capture this heterogeneity and for a deeper
understanding of leukemogenesis and AML cells’ communication with the microenvironment.
Supplementary Materials: The following are available online http://www.mdpi.com/2227-7382/7/1/1/s1,
Supplemental Table S1: Levels of constitutive cytokine release during in vitro culture by enriched primary human
AML cells. For each mediator, we present the number of patients (n = 19 patient samples were included) with
detectable levels, together with the median level (pg/mL) and the range for those patients showing detectable
levels when measured with Luminex/ELISA assays. The mediators showing detectable levels in the proteomic
examination are marked with an asterisk to the left in the figure. Supplemental Table S2: Proteomic LFQ results
for the relevant proteins, and concentration of the constitutively released mediators.
Author Contributions: Conceptualization, Ø.B.; methodology, E.A., M.H.-V., A.K.B., F.S.B and F.S.; formal
analysis, Ø.B., E.A. and A.K.B.; writing—original draft preparation, Ø.B. and E.A.; writing—review and editing,
Ø.B., E.A., A.K.B., F.S., M.H.-V. and F.S.B.; project administration, Ø.B.
Funding: This research received no external funding. The authors receive financial support from the Norwegian
Cancer Society, the Western Norway Regional Health Authority and University of Bergen.
Acknowledgments: The technical assistance of Kristin Paulsen Rye, Marie Hagen and Bram Burger is
gratefully acknowledged.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Döhner, H.; Estey, E.; Grimwade, D.; Amadori, S.; Appelbaum, F.R.; Buchner, T.; Dombret, H.; Ebert, B.L.;
Fenaux, P.; Larson, R.A.; et al. Diagnosis and management of AML in adults: 2017 ELN recommendations
from an international expert panel. Blood 2017, 129, 424–447. [CrossRef] [PubMed]
2. Ehninger, A.; Trumpp, A. The bone marrow stem cell niche grows up: Mesenchymal stem cells and
macrophages move in. J. Exp. Med. 2011, 208, 421–428. [CrossRef] [PubMed]
3. Bruserud, Ø.; Aasebø, E.; Hernandez-Valladares, M.; Tsykunova, G.; Reikvam, H. Therapeutic targeting of
leukemic stem cells in acute myeloid leukemia—The biological background for possible strategies. Expert
Opin. Drug Discov. 2017, 12, 1053–1065. [CrossRef] [PubMed]
4. Reikvam, H.; Brenner, A.K.; Hagen, K.M.; Liseth, K.; Skrede, S.; Hatfield, K.J.; Bruserud, Ø.
The cytokine-mediated crosstalk between primary human acute myeloid cells and mesenchymal stem
cells alters the local cytokine network and the global gene expression profile of the mesenchymal cells.
Stem Cell Res. 2015, 15, 530–541. [CrossRef] [PubMed]
Proteomes 2019, 7, 1 9 of 10
5. Brenner, A.K.; Nepstad, I.; Bruserud, Ø. Mesenchymal Stem Cells Support Survival and Proliferation
of Primary Human Acute Myeloid Leukemia Cells through Heterogeneous Molecular Mechanisms.
Front. Immunol. 2017, 8, 106. [CrossRef] [PubMed]
6. Ito, S.; Barrett, A.J.; Dutra, A.; Pak, E.; Miner, S.; Keyvanfar, K.; Hensel, N.F.; Rezvani, K.; Muranski, P.;
Liu, P.; et al. Long term maintenance of myeloid leukemic stem cells cultured with unrelated human
mesenchymal stromal cells. Stem Cell Res. 2015, 14, 95–104. [CrossRef] [PubMed]
7. Löwenberg, B.; van Putten, W.L.; Touw, I.P.; Delwel, R.; Santini, V. Autonomous proliferation of leukemic
cells in vitro as a determinant of prognosis in adult acute myeloid leukemia. N. Engl. J. Med. 1993, 328,
614–619. [CrossRef]
8. Aasebø, E.; Mjaavatten, O.; Vaudel, M.; Farag, Y.; Selheim, F.; Berven, F.; Bruserud, Ø.;
Hernandez-Valladares, M. Freezing effects on the acute myeloid leukemia cell proteome and
phosphoproteome revealed using optimal quantitative workflows. J. Proteom. 2016, 145, 214–225. [CrossRef]
9. Aasebø, E.; Vaudel, M.; Mjaavatten, O.; Gausdal, G.; Van der Burgh, A.; Gjertsen, B.T.; Døskeland, S.O.;
Bruserud, Ø.; Berven, F.S.; Selheim, F. Performance of super-SILAC based quantitative proteomics for
comparison of different acute myeloid leukemia (AML) cell lines. Proteomics 2014, 14, 1971–1976. [CrossRef]
[PubMed]
10. Aasebø, E.; Forthun, R.B.; Berven, F.; Selheim, F.; Hernandez-Valladares, M. Global Cell Proteome Profiling,
Phospho-signaling and Quantitative Proteomics for Identification of New Biomarkers in Acute Myeloid
Leukemia Patients. Curr. Pharm. Biotechnol. 2016, 17, 52–70. [CrossRef] [PubMed]
11. Hernandez-Valladares, M.; Aasebø, E.; Mjaavatten, O.; Vaudel, M.; Bruserud, Ø.; Berven, F.; Selheim, F.
Reliable FASP-based procedures for optimal quantitative proteomic and phosphoproteomic analysis on
samples from acute myeloid leukemia patients. Biol. Proced. Online 2016, 18, 13. [CrossRef] [PubMed]
12. Honnemyr, M.; Bruserud, Ø.; Brenner, A.K. The constitutive protease release by primary human acute
myeloid leukemia cells. J. Cancer Res. Clin. Oncol. 2017, 143, 1985–1998. [CrossRef] [PubMed]
13. Brenner, A.K.; Tvedt, T.H.; Nepstad, I.; Rye, K.P.; Hagen, K.M.; Reikvam, H.; Bruserud, Ø. Patients with
acute myeloid leukemia can be subclassified based on the constitutive cytokine release of the leukemic cells;
the possible clinical relevance and the importance of cellular iron metabolism. Expert Opin. Ther. Targets
2017, 21, 357–369. [CrossRef] [PubMed]
14. Bruserud, Ø.; Hovland, R.; Wergeland, L.; Huang, T.S.; Gjertsen, B.T. Flt3-mediated signaling in human
acute myelogenous leukemia (AML) blasts: A functional characterization of Flt3-ligand effects in AML cell
populations with and without genetic Flt3 abnormalities. Haematologica 2003, 88, 416–428. [PubMed]
15. Bruserud, Ø.; Gjertsen, B.T.; Foss, B.; Huang, T.S. New strategies in the treatment of acute myelogenous
leukemia (AML): In vitro culture of aml cells—The present use in experimental studies and the possible
importance for future therapeutic approaches. Stem Cells 2001, 19, 1–11. [CrossRef] [PubMed]
16. Gjertsen, B.T.; Øyan, A.M.; Marzolf, B.; Hovland, R.; Gausdal, G.; Døskeland, S.O.; Dimitrov, K.; Golden, A.;
Kalland, K.H.; Hood, L.; et al. Analysis of acute myelogenous leukemia: Preparation of samples for genomic
and proteomic analyses. J. Hematother. Stem Cell Res. 2002, 11, 469–481. [CrossRef] [PubMed]
17. Kulak, N.A.; Pichler, G.; Paron, I.; Nagaraj, N.; Mann, M. Minimal, encapsulated proteomic-sample processing
applied to copy-number estimation in eukaryotic cells. Nat. Methods 2014, 11, 319–324. [CrossRef]
18. Cox, J.; Mann, M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass
accuracies and proteome-wide protein quantification. Nat. Biotechnol. 2008, 26, 1367–1372. [CrossRef]
19. Cox, J.; Hein, M.Y.; Luber, C.A.; Paron, I.; Nagaraj, N.; Mann, M. Accurate proteome-wide label-free
quantification by delayed normalization and maximal peptide ratio extraction, termed MaxLFQ.
Mol. Cell. Proteom. 2014, 13, 2513–2526. [CrossRef]
20. Bruserud, Ø.; Ryningen, A.; Olsnes, A.M.; Stordrange, L.; Øyan, A.M.; Kalland, K.H.; Gjertsen, B.T.
Subclassification of patients with acute myelogenous leukemia based on chemokine responsiveness and
constitutive chemokine release by their leukemic cells. Haematologica 2007, 92, 332–341. [CrossRef]
21. Brenner, A.K.; Reikvam, H.; Bruserud, Ø. A Subset of Patients with Acute Myeloid Leukemia Has Leukemia
Cells Characterized by Chemokine Responsiveness and Altered Expression of Transcriptional as well as
Angiogenic Regulators. Front. Immunol. 2016, 7, 205. [CrossRef] [PubMed]
22. Glenjen, N.; Ersvaer, E.; Ryningen, A.; Bruserud, Ø. In vitro effects of native human acute myelogenous
leukemia blasts on fibroblasts and osteoblasts. Int. J. Cancer 2004, 111, 858–867. [CrossRef]
Proteomes 2019, 7, 1 10 of 10
23. Hatfield, K.; Ryningen, A.; Corbascio, M.; Bruserud, Ø. Microvascular endothelial cells increase proliferation
and inhibit apoptosis of native human acute myelogenous leukemia blasts. Int. J. Cancer 2006, 119, 2313–2321.
[CrossRef] [PubMed]
24. Bruserud, Ø.; Ryningen, A.; Wergeland, L.; Glenjen, N.I.; Gjertsen, B.T. Osteoblasts increase proliferation and
release of pro-angiogenic interleukin 8 by native human acute myelogenous leukemia blasts. Haematologica
2004, 89, 391–402. [PubMed]
25. Brenner, A.K.; Aasebø, E.; Hernandez-Valladares, M.; Selheim, F.; Berven, F.; Bruserud, Ø. Rethinking the role
of osteopontin in human acute myeloid leukemia. Leuk Lymphoma 2017, 58, 1494–1497. [CrossRef] [PubMed]
26. Santos, S.C.; Dias, S. Internal and external autocrine VEGF/KDR loops regulate survival of subsets of acute
leukemia through distinct signaling pathways. Blood 2004, 103, 3883–3889. [CrossRef] [PubMed]
27. Martín-Duque, P.; Quintanilla, M.; McNeish, I.; Lopes, R.; Romero, J.; Romero, D.; Lemoine, N.R.; Ramón y
Cajal, S.; Vassaux, G. Caspase-1 as a radio- and chemo-sensitiser in vitro and in vivo. Int. J. Mol. Med. 2006,
17, 841–847. [CrossRef] [PubMed]
28. Schulz, R. Intracellular targets of matrix metalloproteinase-2 in cardiac disease: Rationale and therapeutic
approaches. Annu. Rev. Pharmacol. Toxicol. 2007, 47, 211–242. [CrossRef] [PubMed]
29. Christensen, S.; Purslow, P.P. The role of matrix metalloproteinases in muscle and adipose tissue development
and meat quality: A review. Meat Sci. 2016, 119, 138–146. [CrossRef] [PubMed]
30. Strongin, A.Y. Proteolytic and non-proteolytic roles of membrane type-1 matrix metalloproteinase in
malignancy. Biochim. Biophys. Acta 2010, 1803, 133–141. [CrossRef] [PubMed]
31. Lambert, E.; Dassé, E.; Haye, B.; Petitfrère, E. TIMPs as multifacial proteins. Crit. Rev. Oncol. Hematol. 2004,
49, 187–198. [CrossRef] [PubMed]
32. Luo, Z.; Zeng, W.; Tang, W.; Long, T.; Zhang, J.; Xie, X.; Kuang, Y.; Chen, M.; Su, J.; Chen, X. CD147 interacts
with NDUFS6 in regulating mitochondrial complex I activity and the mitochondrial apoptotic pathway in
human malignant melanoma cells. Curr. Mol. Med. 2014, 14, 1252–1264. [CrossRef] [PubMed]
33. Liang, Q.; Han, Q.; Huang, W.; Nan, G.; Xu, B.Q.; Jiang, J.L.; Chen, Z.N. HAb18G/CD147 regulates
vinculin-mediated focal adhesion and cytoskeleton organization in cultured human hepatocellular carcinoma
cells. PLoS ONE 2014, 9, e102496. [CrossRef] [PubMed]
34. Soh, H.; Venkatesan, N.; Veena, M.S.; Ravichandran, S.; Zinabadi, A.; Basak, S.K.; Parvatiyar, K.;
Srivastava, M.; Liang, L.J.; Gjertson, D.W.; et al. Cystatin E/M Suppresses Tumor Cell Growth through
Cytoplasmic Retention of NF-kappaB. Mol. Cell. Biol. 2016, 36, 1776–1792. [CrossRef] [PubMed]
35. Wallin, H.; Abrahamson, M.; Ekström, U. Cystatin C properties crucial for uptake and inhibition of
intracellular target enzymes. J. Biol. Chem. 2013, 288, 17019–17029. [CrossRef] [PubMed]
36. Riccio, M.; Di Giaimo, R.; Pianetti, S.; Palmieri, P.P.; Melli, M.; Santi, S. Nuclear localization of cystatin B, the
cathepsin inhibitor implicated in myoclonus epilepsy (EPM1). Exp. Cell Res. 2001, 262, 84–94. [CrossRef]
[PubMed]
37. Casado, P.; Hijazi, M.; Britton, D.; Cutillas, P.R. Impact of phosphoproteomics in the translation of
kinase-targeted therapies. Proteomics 2017, 17. [CrossRef]
38. Ryningen, A.; Ersvaer, E.; Øyan, A.M.; Kalland, K.H.; Vintermyr, O.K.; Gjertsen, B.T.; Bruserud, Ø.
Stress-induced in vitro apoptosis of native human acute myelogenous leukemia (AML) cells shows a wide
variation between patients and is associated with low BCL-2:Bax ratio and low levels of heat shock protein
70 and 90. Leuk. Res. 2006, 30, 1531–1540. [CrossRef]
39. Wangen, R.; Aasebø, E.; Trentani, A.; Døskeland, S.O.; Bruserud, Ø.; Selheim, F.; Hernandez-Valladares, M.
Preservation Method and Phosphate Buffered Saline Washing Affect the Acute Myeloid Leukemia Proteome.
Int. J. Mol. Sci. 2018, 19, 296. [CrossRef]
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
